wer kennt LUMINEX ??? - 500 Beiträge pro Seite
eröffnet am 16.07.00 11:34:01 von
neuester Beitrag 01.04.02 23:46:31 von
neuester Beitrag 01.04.02 23:46:31 von
Beiträge: 9
ID: 186.577
ID: 186.577
Aufrufe heute: 0
Gesamt: 510
Gesamt: 510
Aktive User: 0
ISIN: US55027E1029 · WKN: 936597
31,42
EUR
+0,74 %
+0,23 EUR
Letzter Kurs 14.07.21 Tradegate
Neuigkeiten
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,0700 | +75,41 | |
1,4900 | +73,46 | |
0,7500 | +50,00 | |
1,5400 | +33,91 | |
0,7630 | +26,53 |
Wertpapier | Kurs | Perf. % |
---|---|---|
5,0101 | -15,80 | |
3,8500 | -16,12 | |
7,5000 | -16,67 | |
1,8500 | -20,94 | |
3,6400 | -38,62 |
wer kennt LUMINEX(936597)???seht euch mal den chart an.wer hat infos?
gute geschäfte
thebull 2
gute geschäfte
thebull 2
für alle interessierten.
http://www.luminexcorp.com/products/
sehr interesesant meiner meinung nach.
gute geschäfte
thebull 2
http://www.luminexcorp.com/products/
sehr interesesant meiner meinung nach.
gute geschäfte
thebull 2
Luminex macht gerade eine nette Bodenbildung ,ich denke der Ausbruch
steht unmittelbar bevor. (60 min stochastik,...)
sind übrigens kein Zockerwert,sondern gehören mit, nach dem absturz ,immer noch über 400Mill.$ Marktcap.
zu den großen im Bio EMERGING TECHNOLOGIES BEREICH (mit Affymetrix ,Caliper, Lion Bioscience,packard Bioscience)
Ipo war am 30.3 2000
Absturz war weil der Umsatz fürs erste q von 4.2 auf 3.9Mill revidiert wurde.
Ist aber sicher im Kurs und die Aussichten sind weiter positiv
steht unmittelbar bevor. (60 min stochastik,...)
sind übrigens kein Zockerwert,sondern gehören mit, nach dem absturz ,immer noch über 400Mill.$ Marktcap.
zu den großen im Bio EMERGING TECHNOLOGIES BEREICH (mit Affymetrix ,Caliper, Lion Bioscience,packard Bioscience)
Ipo war am 30.3 2000
Absturz war weil der Umsatz fürs erste q von 4.2 auf 3.9Mill revidiert wurde.
Ist aber sicher im Kurs und die Aussichten sind weiter positiv
@thebull2
alle achtung,dein letztes posting vom 2.5. - man beachte den zeitpunkt..... gut !
alle achtung,dein letztes posting vom 2.5. - man beachte den zeitpunkt..... gut !
moin berniek
sorry,aber ich weiss nicht was du meinst.
gruss
tb 2
sorry,aber ich weiss nicht was du meinst.
gruss
tb 2
ganz einfach, von nun an gings `berg auf`...............
@berniek
sorry aber ich kann dir immer noch nicht folgen.
was hab ich denn am 2.5.gepostet???
kann es sein das du mich mit 4now verwechselst?
gruss
tb 2
sorry aber ich kann dir immer noch nicht folgen.
was hab ich denn am 2.5.gepostet???
kann es sein das du mich mit 4now verwechselst?
gruss
tb 2
Thursday August 23, 7:31 am Eastern Time
Press Release
SOURCE: Luminex Corporation
Luminex and Hitachi Software Announce Distribution and Agency Agreement
For Japan
- MiraiBio, Hitachi Software Engineering, and DNA Chip Research Sign On As Luminex`s Sole
Japan-Based Agents -
AUSTIN, Texas, ALAMEDA, Calif. and YOKOHAMA, Japan, Aug. 23 /PRNewswire/ -- Luminex Corporation (Nasdaq:
LMNX - news) and MiraiBio, Inc.(MBI), a subsidiary of Hitachi Software Engineering, Co., Ltd.(HSW), announced today that
they have entered into a multi-year agreement that appoints HSW and DNA Chip Research, Inc. (DCR) through MiraiBio as
Luminex`s sole Japan-based agents.
HSW and DCR have rights to authorize additional strategic partners in Japan who are expected to utilize the Luminex technology
for a wide variety of products and services. Luminex will receive royalties based on the products commercialized and services
performed by these Japanese strategic partners. HSW and DCR also have rights to distribute Luminex instruments and
consumables in Japan. This agreement complements and expands the previous distribution agreement that Luminex and MiraiBio
announced last year.
Under the agreement, MBI has agreed to purchase over $3.0 million of Luminex systems over the next 15 months.
``We are thrilled to embark on this close relationship with Luminex. We are ideally situated to represent the Luminex technology in
Japan,`` stated Leonard Klevan, MBI`s President and CEO. ``The Japanese market represents a major opportunity for the
introduction of advanced, innovative methods for bioassay development based upon the Luminex technology platform.``
``Because the LabMAP technology can be applied to biological tests in every area of the life science industry, it was important
that Luminex acquire a partner with marketing and technical expertise throughout this field,`` stated Mark Chandler, Luminex`s
Chairman and CEO. ``Hitachi Software Engineering and its associated companies met this requirement perfectly. We are
confident that our current customers in Japan will be excited to have the support of such a powerful and well-respected
company.``
Luminex`s proprietary open platform LabMAP technology can perform up to 100 assays simultaneously on a single drop of fluid
with the capability for both medium and high-throughput assay applications. This system combines the use of low-cost
microsphere-based assays with small lasers, advanced digital signal processors and proprietary software to offer greater speed,
precision and flexibility over other current bioassay technologies.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The
company`s LabMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as
diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research. The LabMAP system is sold worldwide and is already in use in leading
research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or LabMAP can be
obtained on the Internet at http://www.luminexcorp.com .
About MiraiBio, Inc.
MiraiBio, Inc (formerly the Genetic Systems Division of Hitachi Software Engineering America, Ltd.), was spun off as a subsidiary dedicated to serving the life
sciences market. MiraiBio delivers proven solutions for life science research in fields such as genomics, proteomics, drug discovery, and forensics. The company
offers products for bioimaging, microarrays, bioinformatics, and spectroscopy. Bioimaging products include fluorescence and CCD-based imaging systems.
Microarray systems include an automated spotter, and data management software. Next-generation spectroscopy instruments for DNA/RNA/protein measurements
with full UV/Visible scans expands the product line. A preview of the company and its products can be obtained on the Internet at http://www.miraibio.com .
About Hitachi Software Engineering, Co., Ltd.
Hitachi Software Engineering Co., Ltd., (HSW) is a publicly traded company on the First Section of Tokyo Stock Exchange, with net sales of 1.5 billion dollars in
2000. HSW was established in 1970 as the first software company in The Hitachi Group. Its software products range in application from hand-held computers to
super-computers, and are widely used by financial institutions, government agencies, utility companies and others. HSW took advantage of its depth of accumulated
technology know-how, and its reputation for superior quality and reliability when, in 1983, it moved into the life sciences market with the introduction of DNASIS
software. HSW continues its advance into the life sciences market by offering products for microarrays, and advanced bioinformatics. A preview of the company
and its products can be obtained on the Internet at http://www.hitachi-sk.co.jp .
Statements made in this press release that express Luminex`s or management`s intentions, plans, beliefs, expectations or predictions of future events are
forward-looking statements. The words ``believe,`` ``expect,`` ``intend,`` ``estimate,`` ``anticipate,`` ``will`` and similar expressions are intended to further identify such
forward-looking statements. It is important to note that the company`s actual results or performance could differ materially from those anticipated or projected in
such forward-looking statements. Factors that could cause Luminex`s actual results or performance to differ materially include risks and uncertainties relating to
market demand and acceptance of Luminex`s products, the company`s dependence on strategic partners for development and distribution of products, the
company`s ability to protect its intellectual property in Japan, competition, Luminex`s ability to scale-up manufacturing operations, potential shortages of components
and the timing of regulatory approvals, as well as the risks discussed under the heading ``Factors That May Affect Future Results`` in Luminex`s annual report on
Form 10-K for the year ended December 31, 2000 and Form 10-Q for the quarter ended March 31, 2001, as filed with the Securities and Exchange Commission.
The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent,
obligation or undertaking to update or revise such forward-looking statements to reflect any change in Luminex`s expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are based.
Editor`s Note:
Information on MiraiBio can be found on the Internet at http://www.miraibio.com .
Information on Hitachi Software Engineering, Ltd. can be found on the Internet at http://www.hitachi-sk.co.jp/English/index.html .
Information on Luminex and LabMAP(TM) can be found on the Internet at http://www.luminexcorp.com .
Contacts:
MiraiBio, Inc.
(a subsidiary of Hitachi Software Engineering, Co., Ltd.)
(510) 337-2034
Leonard Klevan
President
CONTACT INFO in JAPAN
Hitachi Software Engineering, Co., Ltd.
011-81-45-681-2111
Masafumi Shimoda
General Manager
Life Science Promotion Division
Luminex Corporation
(512) 219-8020
Frank Reeves
Chief Financial Officer
SOURCE: Luminex Corporation
gruss
tb 2
Press Release
SOURCE: Luminex Corporation
Luminex and Hitachi Software Announce Distribution and Agency Agreement
For Japan
- MiraiBio, Hitachi Software Engineering, and DNA Chip Research Sign On As Luminex`s Sole
Japan-Based Agents -
AUSTIN, Texas, ALAMEDA, Calif. and YOKOHAMA, Japan, Aug. 23 /PRNewswire/ -- Luminex Corporation (Nasdaq:
LMNX - news) and MiraiBio, Inc.(MBI), a subsidiary of Hitachi Software Engineering, Co., Ltd.(HSW), announced today that
they have entered into a multi-year agreement that appoints HSW and DNA Chip Research, Inc. (DCR) through MiraiBio as
Luminex`s sole Japan-based agents.
HSW and DCR have rights to authorize additional strategic partners in Japan who are expected to utilize the Luminex technology
for a wide variety of products and services. Luminex will receive royalties based on the products commercialized and services
performed by these Japanese strategic partners. HSW and DCR also have rights to distribute Luminex instruments and
consumables in Japan. This agreement complements and expands the previous distribution agreement that Luminex and MiraiBio
announced last year.
Under the agreement, MBI has agreed to purchase over $3.0 million of Luminex systems over the next 15 months.
``We are thrilled to embark on this close relationship with Luminex. We are ideally situated to represent the Luminex technology in
Japan,`` stated Leonard Klevan, MBI`s President and CEO. ``The Japanese market represents a major opportunity for the
introduction of advanced, innovative methods for bioassay development based upon the Luminex technology platform.``
``Because the LabMAP technology can be applied to biological tests in every area of the life science industry, it was important
that Luminex acquire a partner with marketing and technical expertise throughout this field,`` stated Mark Chandler, Luminex`s
Chairman and CEO. ``Hitachi Software Engineering and its associated companies met this requirement perfectly. We are
confident that our current customers in Japan will be excited to have the support of such a powerful and well-respected
company.``
Luminex`s proprietary open platform LabMAP technology can perform up to 100 assays simultaneously on a single drop of fluid
with the capability for both medium and high-throughput assay applications. This system combines the use of low-cost
microsphere-based assays with small lasers, advanced digital signal processors and proprietary software to offer greater speed,
precision and flexibility over other current bioassay technologies.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The
company`s LabMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as
diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research. The LabMAP system is sold worldwide and is already in use in leading
research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or LabMAP can be
obtained on the Internet at http://www.luminexcorp.com .
About MiraiBio, Inc.
MiraiBio, Inc (formerly the Genetic Systems Division of Hitachi Software Engineering America, Ltd.), was spun off as a subsidiary dedicated to serving the life
sciences market. MiraiBio delivers proven solutions for life science research in fields such as genomics, proteomics, drug discovery, and forensics. The company
offers products for bioimaging, microarrays, bioinformatics, and spectroscopy. Bioimaging products include fluorescence and CCD-based imaging systems.
Microarray systems include an automated spotter, and data management software. Next-generation spectroscopy instruments for DNA/RNA/protein measurements
with full UV/Visible scans expands the product line. A preview of the company and its products can be obtained on the Internet at http://www.miraibio.com .
About Hitachi Software Engineering, Co., Ltd.
Hitachi Software Engineering Co., Ltd., (HSW) is a publicly traded company on the First Section of Tokyo Stock Exchange, with net sales of 1.5 billion dollars in
2000. HSW was established in 1970 as the first software company in The Hitachi Group. Its software products range in application from hand-held computers to
super-computers, and are widely used by financial institutions, government agencies, utility companies and others. HSW took advantage of its depth of accumulated
technology know-how, and its reputation for superior quality and reliability when, in 1983, it moved into the life sciences market with the introduction of DNASIS
software. HSW continues its advance into the life sciences market by offering products for microarrays, and advanced bioinformatics. A preview of the company
and its products can be obtained on the Internet at http://www.hitachi-sk.co.jp .
Statements made in this press release that express Luminex`s or management`s intentions, plans, beliefs, expectations or predictions of future events are
forward-looking statements. The words ``believe,`` ``expect,`` ``intend,`` ``estimate,`` ``anticipate,`` ``will`` and similar expressions are intended to further identify such
forward-looking statements. It is important to note that the company`s actual results or performance could differ materially from those anticipated or projected in
such forward-looking statements. Factors that could cause Luminex`s actual results or performance to differ materially include risks and uncertainties relating to
market demand and acceptance of Luminex`s products, the company`s dependence on strategic partners for development and distribution of products, the
company`s ability to protect its intellectual property in Japan, competition, Luminex`s ability to scale-up manufacturing operations, potential shortages of components
and the timing of regulatory approvals, as well as the risks discussed under the heading ``Factors That May Affect Future Results`` in Luminex`s annual report on
Form 10-K for the year ended December 31, 2000 and Form 10-Q for the quarter ended March 31, 2001, as filed with the Securities and Exchange Commission.
The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent,
obligation or undertaking to update or revise such forward-looking statements to reflect any change in Luminex`s expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are based.
Editor`s Note:
Information on MiraiBio can be found on the Internet at http://www.miraibio.com .
Information on Hitachi Software Engineering, Ltd. can be found on the Internet at http://www.hitachi-sk.co.jp/English/index.html .
Information on Luminex and LabMAP(TM) can be found on the Internet at http://www.luminexcorp.com .
Contacts:
MiraiBio, Inc.
(a subsidiary of Hitachi Software Engineering, Co., Ltd.)
(510) 337-2034
Leonard Klevan
President
CONTACT INFO in JAPAN
Hitachi Software Engineering, Co., Ltd.
011-81-45-681-2111
Masafumi Shimoda
General Manager
Life Science Promotion Division
Luminex Corporation
(512) 219-8020
Frank Reeves
Chief Financial Officer
SOURCE: Luminex Corporation
gruss
tb 2
Luminex Corporation Provides Preliminary First Quarter 2002 ...
Alle Nachrichten
01.04. / 23:31
< zurück <
> Archiv >
Luminex Corporation announced today that it expects first quarter 2002 revenue and earnings to be significantly
below the Company`s earlier guidance as a result of continuing delays in the commercialization timetables of a
number of its strategic partners. Based on a preliminary analysis of first quarter shipments, revenues currently are
expected to be in the range of $2.2 to $2.7 million. At this level of revenue, the Company estimates diluted loss
per share will be in the range of $0.20 to $0.23 for the quarter ended March 31, 2002.
Commenting on the revised outlook, Mark Chandler, Luminex Chairman and CEO, said, "Our revenues continue to
be negatively affected by the lengthy and unpredictable sales cycle for the Company`s instruments and
consumable products. Contributing to the current quarter`s shortfall was a change in the Company`s pricing
strategy to eliminate end-of-quarter discounting. Similar to a number of companies in hardware- and
software-based industries, significant sales of the Company`s products have occurred in the last two weeks of the
quarter. We feel strongly that this change in pricing strategy is vital to the long-term success of the Company. It
should enhance our margins and spread sales more evenly over the quarter, thereby providing a clearer picture of
the acceptance of the Luminex technology for management, the investment community and our stockholders."
Dr. Chandler continued, "We remain extremely optimistic about the market acceptance of the Luminex(R) platform.
Our limited operating history and reliance on strategic partners to market our products, however, makes
forecasting quarter to quarter, as well as annual revenue and operating results, extremely difficult. We currently
expect full-year 2002 revenues to fall below previously announced annual guidance of $35 to $40 million. We will
be prepared to discuss our financial outlook for the remainder of 2002 in greater detail during our regularly
scheduled first quarter 2002 earnings conference call to be held later this month."
Luminex will host a conference call to discuss the preliminary 2002 first quarter financial outlook at 5:00 p.m.
Eastern Standard Time on April 1, 2002. The call will be available via Web cast live at
http://www.luminexcorp.com/ . Simply log on to the web at the address above and access the Investor Relations
link.
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with
applications throughout the life sciences industry. The Company`s xMAP(TM) system is an open-architecture, multi-
analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse
as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and
proteomics research markets. The Company`s xMAP technology is sold worldwide and is already in use in leading
research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further
information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com/ .
Statements made in this press release that express Luminex`s or management`s intentions, plans, beliefs,
expectations or predictions of future events are forward-looking statements. The words "believe," "expect,"
"intend," "estimate," "anticipate," "will" and similar expressions are intended to further identify such
forward-looking statements. It is important to note that the Company`s actual results or performance could differ
materially from those anticipated or projected in such forward-looking statements. Factors that could cause
Luminex`s actual results or performance to differ materially include risks and uncertainties relating to fluctuations in
quarterly results due to a lengthy and unpredictable sales cycle, market demand and acceptance of Luminex`s
products, the Company`s dependence on strategic partners for development, commercialization and distribution of
products, competition, Luminex`s ability to scale-up manufacturing operations, potential shortages of components
and the timing of regulatory approvals, as well as the risks discussed under the heading "Factors That May Affect
Future Results" in Luminex`s Form 10-K for the year ended December 31, 2001, as filed with the Securities and
Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of
the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to update or
revise such forward-looking statements to reflect any change in Luminex`s expectations with regard thereto or any
change in events, conditions or circumstances on which any such statements are based.
Contact: Mark B. Chandler, Ph.D. Chairman & CEO (512) 219-8020
Luminex Corporation
© PR Newswire
gruss
tb 2
Alle Nachrichten
01.04. / 23:31
< zurück <
> Archiv >
Luminex Corporation announced today that it expects first quarter 2002 revenue and earnings to be significantly
below the Company`s earlier guidance as a result of continuing delays in the commercialization timetables of a
number of its strategic partners. Based on a preliminary analysis of first quarter shipments, revenues currently are
expected to be in the range of $2.2 to $2.7 million. At this level of revenue, the Company estimates diluted loss
per share will be in the range of $0.20 to $0.23 for the quarter ended March 31, 2002.
Commenting on the revised outlook, Mark Chandler, Luminex Chairman and CEO, said, "Our revenues continue to
be negatively affected by the lengthy and unpredictable sales cycle for the Company`s instruments and
consumable products. Contributing to the current quarter`s shortfall was a change in the Company`s pricing
strategy to eliminate end-of-quarter discounting. Similar to a number of companies in hardware- and
software-based industries, significant sales of the Company`s products have occurred in the last two weeks of the
quarter. We feel strongly that this change in pricing strategy is vital to the long-term success of the Company. It
should enhance our margins and spread sales more evenly over the quarter, thereby providing a clearer picture of
the acceptance of the Luminex technology for management, the investment community and our stockholders."
Dr. Chandler continued, "We remain extremely optimistic about the market acceptance of the Luminex(R) platform.
Our limited operating history and reliance on strategic partners to market our products, however, makes
forecasting quarter to quarter, as well as annual revenue and operating results, extremely difficult. We currently
expect full-year 2002 revenues to fall below previously announced annual guidance of $35 to $40 million. We will
be prepared to discuss our financial outlook for the remainder of 2002 in greater detail during our regularly
scheduled first quarter 2002 earnings conference call to be held later this month."
Luminex will host a conference call to discuss the preliminary 2002 first quarter financial outlook at 5:00 p.m.
Eastern Standard Time on April 1, 2002. The call will be available via Web cast live at
http://www.luminexcorp.com/ . Simply log on to the web at the address above and access the Investor Relations
link.
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with
applications throughout the life sciences industry. The Company`s xMAP(TM) system is an open-architecture, multi-
analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse
as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and
proteomics research markets. The Company`s xMAP technology is sold worldwide and is already in use in leading
research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further
information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com/ .
Statements made in this press release that express Luminex`s or management`s intentions, plans, beliefs,
expectations or predictions of future events are forward-looking statements. The words "believe," "expect,"
"intend," "estimate," "anticipate," "will" and similar expressions are intended to further identify such
forward-looking statements. It is important to note that the Company`s actual results or performance could differ
materially from those anticipated or projected in such forward-looking statements. Factors that could cause
Luminex`s actual results or performance to differ materially include risks and uncertainties relating to fluctuations in
quarterly results due to a lengthy and unpredictable sales cycle, market demand and acceptance of Luminex`s
products, the Company`s dependence on strategic partners for development, commercialization and distribution of
products, competition, Luminex`s ability to scale-up manufacturing operations, potential shortages of components
and the timing of regulatory approvals, as well as the risks discussed under the heading "Factors That May Affect
Future Results" in Luminex`s Form 10-K for the year ended December 31, 2001, as filed with the Securities and
Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of
the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to update or
revise such forward-looking statements to reflect any change in Luminex`s expectations with regard thereto or any
change in events, conditions or circumstances on which any such statements are based.
Contact: Mark B. Chandler, Ph.D. Chairman & CEO (512) 219-8020
Luminex Corporation
© PR Newswire
gruss
tb 2
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
-0,42 | |
-0,94 | |
+0,22 | |
-1,79 | |
+11,83 | |
+0,85 | |
+0,95 | |
+0,13 | |
+1,55 | |
0,00 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
120 | ||
74 | ||
49 | ||
40 | ||
37 | ||
37 | ||
36 | ||
35 | ||
34 | ||
32 |